CAR-T Therapy Market Definition

The chimeric antigen receptor -T therapy market consists of sales of CAR-T therapy products and related services by entities (organizations, sole traders and partnerships) that develop chimeric antigen receptor (CAR) T-cell therapies to treat blood cancers. CAR-T therapy is type of immunotherapy in which T-cells taken from patient’s blood are modified in a laboratory with the addition of a special protein receptor that grants T-cells the power to recognize as well as kill cancer cells easily, along with infusing the same back into that patient. This special protein receptor, known as the chimeric antigen receptor (CAR), attaches to a specific protein on a patient’s cancer cells. The infused cells multiply and prevail in the patient’s body as living drugs. This industry includes establishments that are involved in the research and development to introduce new targeted cell therapies for treating indications related mostly to hematological malignancies. However, some of the pipeline CAR-T therapies are aimed at targeting solid tumors including pancreatic cancer, breast cancer, ovarian cancer, gastric cancer, kidney cancer, brain tumor, and other cancer types.

Anti-Viral Drug Therapy Market Definition

The anti-viral drug therapy market consists of sales of branded and generic anti-viral drugs and related services by entities (organizations, sole traders and partnerships) that manufacture branded or generic anti-viral drugs to treat microbial infections. The anti-viral drug therapy industry includes establishments that manufacture anti-viral drugs, which are used to treat diseases or illnesses caused by viral infections. Examples of antiviral drugs include idoxuridine, famiciclovir, cidofovir, amantadine, zanamivir, tenofovir, adefovir and ribavirin. Viruses are infective agents comprising of a core of nucleic acids, either RNA or DNA, and are surrounded by a layer of protein. These are not living organisms, and can reproduce only inside a living cell. Anti-viral drugs decrease the ability of viruses to reproduce. These drugs enter the cells infected with virus, and interfere with the ability of the virus to bind to the cell, and stimulate the immune system of the host.

Convalescent plasma is plasma that has been collected from people who have recovered or are convalescing and contains antibodies against the infection-causing microorganism.It is used for the treatment of patients infected by the respective pathogen. The main antibody types of convalescent plasma therapy are IgM, IgG, and IgA. Immunoglobulin A (IgA) is an antibody that is essential for mucous membrane immunological activity. The different applications include prophylaxis, and treatment and are used in various sectors such as hospitals and clinics, laboratories, and research institutes. The convalescent plasma therapy market research report is one of a series of new reports from The Business Research Company that provides convalescent plasma therapy market statistics, including convalescent plasma therapy industry global market size, regional shares, competitors with a convalescent plasma therapy market share, detailed convalescent plasma therapy market segments, market trends and opportunities, and any further data you may need to thrive in the convalescent plasma therapy industry. This convalescent plasma therapy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global convalescent plasma therapy market size will grow from $0.04 billion in 2022 to $0.05 billion in 2023 at a compound annual growth rate (CAGR) of 11.4%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The global convalescent plasma therapy market size is expected to grow from $0.07 billion in 2027 at a CAGR of 12.0%. Higher efficacy and safety evaluated during the trials conducted for CPT in COVID-19 patients can drive the market growth during the forecast period. Convalescent plasma transfusion has been of interest in the historical period for the treatment of other infectious disease outbreaks such as SARS-1, Middle East Respiratory Syndrome (MERS), and 2009 H1N1. In June 2020, results of a study conducted by the Houston Methodist hospital, which aimed at evaluating safety and efficacy of COVID-19 convalescent plasma therapy, stated that the convalescent plasma therapy is safe with no adverse events reported and is efficient with 76% recovery rate. In May 2020, a study published in the Journal of Medical Virology stated that with convalescent plasma therapy, the mortality rate may be reduced in critically ill patients, beneficial effects on clinical symptoms will be observed, and an increase in neutralizing antibody titers and disappearance of SARS-CoV-2 RNA will be observed. The safety and efficacy of the convalescent plasma therapy in COVID-19 patients will boost market growth. The availability of scant evidence regarding the safety and efficacy of convalescent plasma therapy led to strict guidelines by government authorities. Different government authorities like the US FDA, CDSCO of India, and others have approved COVID-19 convalescent plasma for investigational use only and not for prescribed indication. In May 2020, FDA released guidelines for COVID-19 convalescent plasma therapy, which stated that the administration of COVID-19 convalescent plasma must be under the investigational new drug application (IND) for clinical trials, expanded access, and single-patient emergency only. Even for a single patient emergency, an eIND must be filed with FDA for the use of convalescent plasma therapy, provided, the health care provider must determine that the probable risk from the investigational drug is not greater than the probable risk from the disease or condition. COVID-19 convalescent plasma should be obtained from an FDA-registered blood establishment that follows the donor eligibility criteria and donor qualifications. The manufacturing process and shelf life should be the same as that of other similar plasma products. These strict guidelines framed by authorities are expected to limit the market growth. The development of antibody-based immunotherapy as a potential therapeutic intervention for COVID-19 shows opportunities for the convalescent plasma therapy market. Convalescent plasma therapy utilizes the antibodies produced against coronavirus by the donor to improve the immunity of the recipient. Companies are initiating trials, collaborating and investing for antibody-based COVID-19 therapy. In April 2020, GSK entered into a collaboration with Vir Biotechnology and invested $250 million in Vir to support the development of anti-viral antibody-based solutions against novel coronavirus. In April 2020, Biomedical Advanced Research Development Authority (BARDA) partnered with Emergent BioSolutions to fund $14.5 million to support the development of human plasma-derived therapy which is COVID-Human Immune Globulin (COVID-HIG) for treating COVID-19 in severe hospitalized and high-risk patients. In April 2020, global plasma companies like CSL Behring, Takeda Pharmaceutical Company Limited, Biotest, BPL, LFB, and Octapharma collaborated to develop plasma-derived COVID-19 Hyperimmune Therapy. As convalescent plasma therapy utilizes antibodies, the focus over antibody-based COVID-19 therapy is expected to boost the market growth. In March 2020, Grifols, a Spain-based multinational pharmaceutical and chemical manufacturer that develops, produces, and markets innovative solutions under divisions - Bioscience, Diagnostic, Hospital and Bio Supplies, announced its collaboration with the United States Biomedical Advanced Research Development Authority (BARDA), the Food and Drug Administration (FDA) and other Federal public health agencies. Under this collaboration, Grifols will collect plasma from FDA-approved plasma collection centres to develop a hyperimmune globulin as a treatment option for COVID-19 patients and will support the convalescent plasma therapy approach by providing inactivated plasma for transfusion using viral inactivation technology (methylene blue). FDA is a federal agency and BARDA is an authority of the United States Department of Health and Human Services that protects public health through the transition of medical products like vaccines, biopharmaceuticals, pharmaceuticals, and others from research to FDA approval for public use. Major players in the convalescent plasma therapy market are Bio Farma, Grifols, Hilton Pharma, Biotest, BPL, LFB, Octapharma, CSL Behring, Takeda Pharmaceutical Company Limited and Orthosera Kft. North America was the largest region in the convalescent plasma therapy market in 2022. Western Europe was the second largest region in the global convalescent plasma therapy market. The regions covered in the global convalescent plasma therapy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the convalescent plasma therapy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA. The convalescent plasma therapy market includes revenue earned by IgD and IgE. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global convalescent plasma therapy market is segmented - 1) By Application: Prophylaxis, Treatment 2) By End-Users: Hospitals & Clinics, Laboratories & Research institutes 3) By Antibody type: IgM, IgG, IgA

Gene therapy is used for correcting defective genes that are responsible for disease development. Nucleic acid-based therapeutics are used to treat genetic disorders and diseases for which there exists no permanent cure, such as anaemia, sickle cell, cystic fibrosis, and thalassemia. The main technologies in nucleic acid-based gene therapy are anti-sense and anti-gene, short inhibitory sequences, gene transfer therapy, nucleoside analogues, ribozymes, aptamers, and others. The nucleoside analogues are a significant class of antiviral agents that are generally utilised in the therapy of human immunodeficiency virus (HIV) infection, hepatitis B virus (HBV), hepatitis C virus (HCV), and cytomegalovirus (CMV). The various applications include oncology, muscular dystrophy, muscular disorders, and rare diseases that are used by end-users such as hospitals and clinics and academic and research institutes. The nucleic acid-based gene therapy market research report is one of a series of new reports from The Business Research Company that provides nucleic acid-based gene therapy market statistics, including nucleic acid-based gene therapy industry global market size, regional shares, competitors with a nucleic acid-based gene therapy market share, detailed nucleic acid-based gene therapy market segments, market trends and opportunities, and any further data you may need to thrive in the nucleic acid-based gene therapy industry. This nucleic acid-based gene therapy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global nucleic acid based gene therapy market grew from $0.68 billion in 2022 to $0.75 billion in 2023 at a compound annual growth rate (CAGR) of 9.7%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The nucleic acid based gene therapy market is expected to grow from $1.06 billion in 2027 at a CAGR of 9.2%. Rising financial support by the government and the companies is projected to drive the demand for nucleic acid-based gene therapy. Nucleic acid therapeutics are analogs of naturally occurring acids or proteins responsible for genetic expression. The traditional therapies do not have any cure for the treatment of diseases such as cystic fibrosis, hemophilia, sickle cell anemia, thalassemia, and diabetes. Genetic profiling and molecular target identification form the backbone of these classes of drugs. Nucleic acid medication has greater potential for the treatment of these diseases, as they target the genetic basis of diseases and have a permanent cure. Rising financial support by the government and the companies dealing in the market for gene therapy is expected to contribute to increasing the demand for nucleic acid-based gene therapies. For instance, in August 2022, National Institute of Health (NIH) announced investment of $34 million annually for upcoming 5 years to develop HIV treatment research. The government support for gene therapies will contribute to the growth of the market. Stringent regulations imposed on gene therapies raise the price of gene therapies, which in turn hinders the demand for nucleic acid-based gene therapies. The excessive regulatory oversights create an expensive and elongated route for approval increasing the expenses. According to Foundation for Economic Education (FEE), unlike other drugs approved or regulated by the Food and Drug Administration (FDA), gene therapies are not only subject to the regulatory structure of the FDA, but also the Recombinant DNA Advisory Committee and Office of Biotechnology Activities. Also, as estimated by FEE, an approved gene therapy drug costs nearly $5.0 billion, which is five times higher than that of the average cost of FDA approval. The high cost of gene therapeutics drugs places them beyond the financial reach of the populace. This scenario is anticipated to restrain the market growth of the nucleic acid-based gene therapy market. The companies in the nucleic acid based gene therapy market are focusing on strategic partnerships and collaborations to help boost production. Major players are entering into partnership to expand their market and leverage each other’s resources. For example, in January 2022, Pfizer Inc., an American multinational pharmaceutical and biotechnology corporation, and Beam Therapeutics Inc., an American biotechnology company developing precision genetic medicines through base editing, announced an exclusive four-year research collaboration focused on in vivo base editing programs for three targets for rare genetic diseases of the liver, muscle and central nervous system. Similarly, in August 2022, Merck, an American multinational pharmaceutical company, and Orna Therapeutics, a US based biotechnology company pioneering a new investigational class of engineered circular RNA (oRNA) therapies, announced a collaboration agreement to discover, develop, and commercialize multiple programs, including vaccines and therapeutics in the areas of infectious disease and oncology. Major players in the nucleic acid-based gene therapy market are Celsion Corporation, Wave Life Sciences, Imugene, Caperna, Phylogica, Protagonist Therapeutics, Benitec Biopharma, EGEN, BioMedica, Transgene, and Copernicus Therapeutics. North America was the largest region in the nucleic acid-based gene therapy market in 2022. Western Europe was the second largest region in the global nucleic acid-based gene therapy market report.The regions covered in the global nucleic acid-based gene therapy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the nucleic acid-based gene therapy market are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA. The nucleic acid based gene therapy market consists of sales of nucleic acid based gene therapy technologies such as anti-sense and anti-gene, short inhibitory sequences, gene transfer therapy, nucleoside analogs, ribozymes, aptamers, and other technologies. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales either further along the supply chain or as part. The global nucleic acid based gene therapy market is segmented - 1) By Technology: Anti-Sence and Anti-Gene, Short Inhibitory Sequences, Gene Transfer Therapy, Nucleoside Analogs, Ribozymes, Aptamers, Other Technologies 2) By Application: Oncology, Muscular Dystrophy/ Muscular Disorders, Rare Diseases 3) By End User: Hospitals And Clinics, Academic And Research Institutes

Transdermal skin patches refer to a drug delivery technique where a pre-prescribed dose of medication is applied as an adhesive patch and absorbed via the skin into the bloodstream. They deliver a precise, pre-set dosage of medication that is absorbed into the bloodstream through the skin. The main types of transdermal skin patches are fentanyl transdermal patches, nicotine transdermal patches, buprenorphine transdermal patches, clonidine transdermal patches, oxybutynin transdermal patches, and others. Nicotine transdermal skin patches are used to assist people in quitting smoking. They provide a source of nicotine through the skin of the human body that helps to alleviate the withdrawal symptoms associated with quitting smoking. The various products used involve a matrix, drugs in the adhesive, reservoir, and vapor that are utilised for pain relief, nicotine cessation, hormone replacement therapy, neurological disorders, cardiovascular disorders, and others. The transdermal skin patches market research report is one of a series of new reports from The Business Research Company that provides transdermal skin patches market statistics, including transdermal skin patches industry global market size, regional shares, competitors with a transdermal skin patches market share, detailed transdermal skin patches market segments, market trends and opportunities, and any further data you may need to thrive in the transdermal skin patches industry. This transdermal skin patches market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry. The global transdermal skin patches market grew from $7.1 billion in 2022 to $7.42 billion in 2023 at a compound annual growth rate (CAGR) of 4.5%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The transdermal skin patches market is expected to grow from $8.43 billion in 2027 at a CAGR of 3.2%. The advances in modern technologies contribute to the growth of the transdermal skin patches market. Advances in modern technologies increase the number of drugs being delivered transdermally including small molecule hydrophobic drugs, hydrophilic drugs, and macromolecules. The new technological advances add to the increased efficiency and increased use of transdermal drug delivery systems (TDDS) thus, increasing the popularity and demand for TDDS. For instance, in September 2022, Corium, a US-based biopharmaceutical company, launched Adlarity, a transdermal patch for treating Alzheimer’s. It is a donepezil transdermal system that distributes donepezil at regular intervals through the skin. It treats people with Alzheimer's-related dementia that is mild, moderate, or severe. Adlarity makes use of the unique Corplex technology from Corium. Over a predetermined period of time, Corplex provides continuous, controlled, and sustained medication release. Stringent regulatory approval by the government regulatory bodies is a key factor hindering the growth of the transdermal skin patches market. The regulatory authority enforces the laws regulating biologics, medications, and medical devices, which can have potential side effects for customers. For instance, Food and Drug Administration (FDA) mandates the TDDS to undergo a series of tests including biomechanical testing, animal testing, and clinical trials before approving the TDDS for use in the market. The whole process consumes time and may result in a delay for the launch of TDDS into the market losing the first-mover advantage thus restraining the growth of the transdermal skin patch market. Major companies in the market are increasingly opting for acquisitions and collaborations to enhance and expand their footprint for the growth of the transdermal skin patches market. The strategic merger and acquisition and collaboration followed by the players in the transdermal skin patches market allow the companies to take technological advantage by acquiring the technology which allows them to get ahead in the competition. For instance, in December 2021, Boyd Corporation, a US-based provider of advanced sealing, thermal management and protection solutions, acquired MBK Tape Solutions for an undisclosed amount. The acquisition enhances Boyd's medical material science expertise in applications including biosensors, transdermal patches, and improved wound care. MBK Tape Solutions is a US-based manufacturer of medical-grade adhesives designed for medical devices, direct wound sealing, or transdermal patches. In June 2020, Nutriband Inc., a USA-based pharmaceutical and healthcare provider that focuses on transdermal and topical technologies, acquired 4P Therapeutics Inc. for an undisclosed amount. Through the acquisition, Nutriband aimed to expand its product portfolio to include transdermal technologies, prescription drugs, and clinical development. 4P Therapeutics Inc. is a U.S.-based biotechnology healthcare research and development company that focuses on novel methods for drug delivery. Major players in the transdermal skin patches market are Mylan Pharmaceuticals Inc., Hisamitsu Pharmaceutical, Novartis, Johnson & Johnson, Teikoku Pharma, Mylan, Actavis, Mundipharma, Henan Lingrui Pharmaceutical, Changzhou Siyao, Rfl Pharmaceutical, Teva, ProSolus Inc., Medipatch Inc., AdhexPharma, Medherant Limited, Nitto Denko, Noven Pharmaceuticals, 3M Pharmaceuticals, Accrux Ltd., Access Pharmaceuticals Inc., Luye Pharma Group Ltd., Purdue Pharma L.P., Abbott Laboratories, Aneva Drug Delivery Systems, Allergan PLC., Corium International Inc., Immune Pharmaceuticals, Hercon Pharmaceuticals, Pocono and DURECT Corporation. North America was the largest region in the global transdermal skin patches market in 2022. The Middle East is expected to be the fastest growing region in the forecast period. The regions covered in the global transdermal skin patches market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa. The countries covered in the transdermal skin patches market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA. The transdermal skin patches market consists of sales of single-layer drug-in-adhesive, multi-layer drug-in-adhesive, and vapour patch. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organisations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the chain or as part of other products. The global transdermal skin patches market is segmented - 1) By Product: Matrix, Drug In Adhesive, Reservoir, Vapor 2) By Type: Fentanyl Transdermal Patch, Nicotine Transdermal Patch, Buprenorphine Transdermal Patch, Clonidine Transdermal Patch, Oxybutynin Transdermal Patch, Other Types 3) By Application: Pain Relief, Nicotine Cessation, Hormone Replacement Therapy, Neurological Disorders, Cardiovascular Disorders, Other Applications

Wound care devices are used to prevent wound infections and promote wound healing. The main types of wound care devices are traditional adhesive dressings, negative-pressure wound therapy (NPWT), Traditional gauze dressings, and advanced wound care devices. Traditional wound dressing products including gauze, lint, plasters, bandages, and cotton wool are dry and used as primary or secondary dressings for protecting the wound from contaminations. The type of expenditure is public and private. The products used are instruments/equipment and disposables. The various end-users are hospitals and clinics, diagnostic laboratories, and others. The wound care devices market research report is one of a series of new reports from The Business Research Company that provides wound care devices market statistics, including wound care devices industry global market size, regional shares, competitors with a wound care devices market share, detailed wound care devices market segments, market trends and opportunities, and any further data you may need to thrive in the wound care devices industry. This wound care devices market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global wound care devices market grew from $55.05 billion in 2022 to $59.79 billion in 2023 at a compound annual growth rate (CAGR) of 8.6%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The wound care devices market is expected to grow to $80.02 billion in 2027 at a CAGR of 7.6%. Combination dressings are increasingly being used to treat chronic wounds. The most widely used combination dressing is an antimicrobial agent and a biological material that together acts as a combination dressing. Combination dressings blend the chemical and physical properties of two or more types of wound dressing products to provide, waterproofing, anti-bacterial and viral infections, and skin-friendly capabilities. For instance, ConvaTec offers AQUACEL combination dressings that are made up of Hydrofiber Technology that incorporates offers stitch bonding functionality and increases the tensile strength of the dressing to be used as a combination dressing with an absorbent for the treatment of chronic wounds. Most widely used combination dressings include silver alginate dressings, silver collagen dressings, collagen hydrochloride dressings, and foam dressings. These dressings are used in the treatment of chronic ulcers, traumatic wounds, and surgical wounds. Wound care device manufacturers should consider focusing on delivering wound care products such as hydrocolloid dressings to improve treatment effectiveness and usage. Hydrocolloid dressing consists of adhesives with gel-forming components composed of either silicone or polyurethane. They are waterproof and self–adhering advanced wound care products that provide a moisture-filled healing environment for the wound. Hydrocolloid bandages are utilized for burns with moderate severity, and granular wounds and protect healed skin by absorbing moisture and swells. For instance, BenQ, a consumer electronics company, offers hydrocolloid dressing which is waterproof, invisible, and against UV rays facilitating high moisture absorption and wound healing. Major companies in the wound care devices market include Medtronic Inc., 3M Company, Smith & Nephew plc, Cardinal Health, Inc., ConvaTec Group Plc, Henry Schein, Inc., Paul Hartmann AG, Essity AB, Coloplast, and Integra Lifesciences. Asia-Pacific was the largest region in the global wound care devices market in 2022. North America was the second largest region in the global wound care devices market. Africa. was the smallest region in the global wound care devices market. The regions covered in the wound care devices market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the wound care devices market are Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, China, Colombia, Czech Republic, Denmark, Egypt, Finland, France, Germany, Hong Kong, India, Indonesia, Ireland, Israel, Italy, Japan, Malaysia, Mexico, Netherlands, New Zealand, Nigeria, Norway, Peru, Philippines, Poland, Portugal, Romania, Russia, Saudi Arabia, Singapore, South Africa., South Korea, Spain, Sweden, Switzerland, Thailand, Turkey, UAE, UK, USA, Venezuela, and Vietnam. The wound care devices market consists of sales of instruments such as non-woven dressings, gauzes, hydrocolloids dressings, and others. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global wound care devices market is segmented - 1) By Type: Traditional Adhesive Dressings, Negative-pressure Wound Therapy (NPWT), Traditional Gauze Dressings, Advanced Wound Care Devices 2) By End User: Hospitals And Clinics, Diagnostic Laboratories, Other End Users 3) By Type of Expenditure: Public, Private 4) By Product: Instruments/Equipment, Disposables

Drugs for immunotherapy refer to a kind of medication that offers treatment to either stimulate or suppress the immune system in order to aid the body's protection against cancer, infection, and other disorders. Your immune system is assisted in fighting cancer via immunotherapy, a sort of cancer treatment. The body's immune system aids in the fight against infections and other disorders. The main types of drugs for immunotherapy are monoclonal antibodies, interferons, interleukins, vaccines, checkpoint inhibitors, and others. Monoclonal antibodies are created by cloning a single white blood cell. Every subsequent antibody generated in this manner may be traced back to a single parent cell. The different areas of therapy include cancer, autoimmune and inflammatory diseases, infectious diseases, and others, and they are used by various sectors such as hospitals and clinics, ambulatory surgical centres, and others. The drugs for immunotherapy market research report is one of a series of new reports from The Business Research Company that provides drugs for immunotherapy market statistics, including drugs for immunotherapy industry global market size, regional shares, competitors with drugs for immunotherapy market share, detailed drugs for immunotherapy market segments, market trends and opportunities, and any further data you may need to thrive in the drugs for immunotherapy industry. This drug for immunotherapy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry. The global drugs for immunotherapy market grew from $208.56 billion in 2022 to $231.12 billion in 2023 at a compound annual growth rate (CAGR) of 10.8%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The drugs for immunotherapy market is expected to grow from $349.53 billion in 2027 at a CAGR of 10.9%. The immunotherapy drugs market is being driven by rising incidences of cancer globally. The major causes of most cancers include obesity, smoking, alcohol, and improper eating habits. For instance, in February 2022, according to a report shared by the WHO, a Switzerland-based specialised agency of the United Nations responsible for international public health, roughly 10 million deaths, or nearly one in six deaths, will be caused by cancer in 2020, making it the top cause of death globally. Breast, lung, colon, rectum, and prostate cancers are the most prevalent types of cancer. The use of tobacco, having a high body mass index, drinking alcohol, eating few fruits and vegetables, and not exercising account for about one-third of cancer-related fatalities. The rising incidences of cancer are expected to increase the demand for immunotherapy drugs driving the market's growth. The high cost of immunotherapy drugs is acting as a restraint on the drugs for the immunotherapy market as a smaller number of patients can afford the treatment. Immunotherapy drugs are expensive as they are made specifically for each patient, and investment costs in the research and development are high. For instance, Novartis’ Kymriah and Gilead Sciences’ Yescarta are two immunotherapy treatments that cost between $373,000 and $475,000 per patient, depending on the type of cancer. The Yervoy (ipilimumab) drug from Bristol-Myers Squibb, for the treatment of melanoma, a type of skin cancer, costs $120,000 per course of treatment. The high cost of immunotherapy drugs makes them unaffordable, thereby affecting their market growth. Manufacturers of immunotherapy drugs are increasingly collaborating or partnering with other companies to share technology, resources, and product knowledge and expand the business. For example, Illumina Inc. and Bristol-Myers Squibb (BMS) collaborated to utilise Illumina’s next-generation sequencing (NGS) technology to develop and commercialize in-vitro diagnostic (IVD) assays in support of Bristol-Myers Squibb's oncology portfolio. Allogene Therapeutics Inc. and Pfizer Inc. entered into an asset contribution agreement to use Pfizer’s portfolio of assets related to allogeneic CAR-T therapy. Manufacturers of immunotherapy drugs are governed by various regulatory bodies, such as the Food and Drug Administration in the USA. The Food and Drug Administration (FDA) regulates drugs and biologics under the authority granted to it by the Federal Food, Drug, and Cosmetic Act (FD&C Act) and its amendments. Under this authority, FDA regulates the pre-market testing and marketing approval for all immunotherapeutic agents, either as drugs or biologics, depending on the source and function of the investigational agent. Immunotherapeutic products that are regulated as biologics include antibodies and proteins, and some nucleic acids. In August 2020, Bristol Myers Squibb, a US-based pharmaceutical company that manufactures prescription pharmaceuticals and biologics in several therapeutic areas, including cancer, HIV/AIDS, cardiovascular disease, diabetes, hepatitis, rheumatoid arthritis, and psychiatric disorders, acquired Dragonfly Therapeutics’ investigational immunotherapy program for $475 million. Through this acquisition, Bristol Myers Squibb will be granted Dragonfly’s extended half-life cytokine DF6002, a monovalent IL-12 immunoglobulin Fc. Dragonfly Therapeutics, Inc. is a US-based discovery-stage company developing drugs to stimulate immune responses against cancer. Major players in the drugs for immunotherapy market are F. Hoffmann-La Roche Ltd., Novartis AG, Amgen, Inc., AbbVie, Inc., and Merck & Co. Inc., GlaxoSmithKline, Eli Lilly and Company, Bristol-Myers Squibb, AstraZeneca PLC., Johnson & Johnson, and UbiVac. North America was the largest region in the immunotherapy market in 2022. The Middle East is expected to be the fastest growing region in the global drug for immunotherapy market during the forecast period. The regions covered in the global drugs for immunotherapy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the drugs for immunotherapy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, USA. The drugs for immunotherapy market consists of sales of cytokines, CAR T-cell therapy, and cancer treatment vaccines. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organisations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the chain or as part of other products. The global drugs for immunotherapy market is segmented - 1) By Type: Monoclonal Antibodies, Interferons, Interleukins, Vaccines, Checkpoint Inhibitors, Other Types 2) By Therapy Area: Cancer, Autoimmune & Inflammatory Diseases, Infectious Diseases, Other Therapy Areas 3) By End User: Hospitals & Clinics, Ambulatory Surgical Centers, Other End Users

The drugs for hormonal replacement therapy are used to treat patients with growth hormone deficiency caused due to conditions such as dwarfism or menopause (a condition that describes changes a woman goes through when her menstruating cycle stops). The drugs for hormonal replacement therapy help to replace low-level hormones from the body, maintain growth hormone deficiency and prevent women from vaginal dryness, mood swings, weakening of bones, and others. The main types of drugs for hormonal replacement therapy are estrogen replacement therapy, human growth hormone (HGH) replacement therapy, thyroid replacement therapy, and testosterone replacement therapy. The various routes of administration are oral, parental, and others which are distributed in hospital pharmacies, retail pharmacies, and online pharmacies. The therapies are applied for hypothyroidism, male hypogonadism, growth hormone deficiency, menopause, and others. The drugs for hormonal replacement therapy market research report is one of a series of new reports from The Business Research Company that provides drugs for hormonal replacement therapy market statistics, including drugs for hormonal replacement therapy industry global market size, regional shares, competitors with drugs for hormonal replacement therapy market share, detailed drugs for hormonal replacement therapy market segments, market trends and opportunities, and any further data you may need to thrive in the drugs for hormonal replacement therapy industry. This drug for hormonal replacement therapy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global drugs for hormonal replacement therapy market size will grow from $12.01 billion in 2022 to $12.66 billion in 2023 at a compound annual growth rate (CAGR) of 5.4%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The global drugs for hormonal replacement therapy market size is expected to grow to $14.63 billion in 2027 at a CAGR of 3.7%. The increasing population of aging and postmenopausal women is driving the drug market for hormonal replacement therapy. Hormonal replacement therapy drugs such as estrogen, progesterone, and others are used to treat medical conditions caused by menopausal conditions. For instance, in February 2021, according to the United Nations Economic and Social Commission for Asia and the Pacific, a Thailand-based regional commission, over half of the people who are over 65 are women, making up over 9% of the total population. By 2050, this percentage is projected to nearly double to more than 18%. From 1.7% to 4.9% of the population, the proportion of people over 80 will almost treble, with women making up over 60% of this group. There are a number of factors that could make older women more vulnerable than older men, including: According to the European Menopause and Andropause Society (EMAS) report, women aged over 60 are expected to reach over 1 billion by 2050. In South Korea, the female population is expected to exceed the male population by 2060, out of which 59.6% of the female population is expected to suffer from postmenopausal symptoms. Thus, the growing female population suffering from menopausal symptoms and the aging population drive the market for hormonal replacement therapy drugs. Increasing the occurrence of side effects due to the intake of drugs for hormonal deficiency may hinder the growth of drugs for the hormonal replacement therapy market. The side effects include vagina dryness, irregular heartbeat, breast swelling, osteoporosis (weakening of bones), and other effects when women undergo hormone replacement therapy. A high dosage of drugs for hormonal replacement therapy may cause rapid heartbeat, bloating (a build-up of gas in the stomach and intestines), nausea, indigestion, vaginal bleeding, blood clots, heart attack, breast cancer, and others. According to an online study, a decrease in the intake of drugs for combined hormone therapy showed a decrease in breast cancer cases by 126,000 and cardiovascular disease cases by 76,000. Thus, the increasing side effects of drugs hinder the growth of drugs for hormonal replacement therapy. Companies in the industry are increasingly developing of drugs for hormonal replacement therapy with better safety profiles and novel drug delivery mechanisms. The drug delivery mechanisms include transdermal estrogen, virginal estrogen, and others. Transdermal estrogen drug delivery is in the form of estradiol transdermal gel, patch, and spray that are used to treat symptoms of menopause, vaginal dryness, itching, burning and others that occur due to low estrogen levels. Varginalestrogen in the form of cream, vaginal ring, and vaginal tablets is used to get the hormone estrogen into the system. For instance, Novo Nordisk, a multinational pharmaceutical company provides novel drug delivery mechanisms and low-dose drugs for hormonal replacement therapy (HRT) to cater to the rising demand of patient needs. Some of the brand’s offerings of novel drugs include Climara, Divigel, Elestrin, Esclim, Estraderm, Estrasorb, EstroGel, Evamist, Oesclim, Rhoxal-EstradiolDerm 50, Vivelle 100 Mcg, Estradot Transdermal Therapeutic System, and others. Department Of Health and Human Services of the Food and Drug Administration (FDA), a federal agency, is a regulatory body that monitors, controls, and regulates the drugs for the hormone replacement therapy market. For instance, the FDA's Department Of Health and Human Services has revised the requirements for specific hormone-containing drug products for human use. These hormones include estrogens, progestins, androgens, anabolic steroids, adrenal corticosteroids, and synthetic analogs. The purpose of the revisal of existing regulations by the FDA is to establish the effectiveness and ensure safety for any over-the-counter drug use of these ingredients. Major players in the drugs for hormonal replacement therapy market are Novartis AG, Bayer AG, Pfizer Inc., Novo Nordisk A/S, Eli Lilly and Company, Abbott, Mylan Laboratories, Merck & Co., Hisamitsu Pharmaceutical Co., Ltd., Teva Pharmaceutical Industries Ltd., F. Hoffmann-La Roche, Noven Pharmaceuticals Inc., Orion Pharma AB, Allergan PLC., QuatRx Pharmaceuticals, Wyeth, Amgen Inc., Roche, Genentech, and TherapeuticsMD. North America was the largest region in the drugs for hormonal replacement therapy market in 2022. The Middle East is expected to be the fastest-growing region in the global drugs for hormonal replacement therapy market during the forecast period. The regions covered in the global drugs for hormonal replacement therapy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the drugs for hormonal replacement therapy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK and USA. The drugs for hormonal replacement therapy market includes revenues earned by entities by treating common menopausal symptoms, including hot flashes and vaginal discomfort. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values – that is, they are revenues generated by organizations in the specified geography within the specified market, irrespective of where they are produced. It does not include revenues from resales either further along the supply chain or as part of other products. The global drugs for hormonal replacement therapy market is segmented - 1) By Therapy Type: Estrogen Replacement Therapy, Human Growth Hormone (HGH) Replacement Therapy, Thyroid Replacement Therapy, Testosterone Replacement Therapy 2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies 3) By Application: Hypothyroidism, Male Hypogonadism, Growth Hormone Deficiency, Menopause, Other Applications 4) By Route of Administration: Oral, Parental, Other Route of Administration